Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying patients with advanced or metastatic non-small cell lung cancer NSCLC to create control groups using current and future patient data. The study aims to generate precision external control arms by observing different patient cohorts categorized by specific genetic mutations and treatment lines. This observational study helps understand treatment responses in real-world settings without assigning specific therapies. Participants are grouped based on their treatment regimens and genetic profiles, such as those starting first-line immune checkpoint inhibitor therapies, patients with actionable EGFR mutations, KRAS mutations, or varying PD-L1 expression levels. The study observes patients receiving standard therapies, such as platinum doublets, targeted agents like osimertinib or lazertinib, or other recommended treatments across different lines of therapy. The study spans from January 2026 to April 2029. During the study, participants response rates to therapies will be assessed, focusing on Objective Response Rate ORR in metastatic NSCLC patients treated in second or third line settings. Secondary measures include progression-free survival, overall survival, and time to next treatment. Participants will be monitored through clinical evaluations and imaging studies to track disease status. This study involves no investigational treatments and aims to gather data from real-world clinical practice over several years.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the TeamBirth quality improvement training program aimed at improving shared decision-making during labor and delivery. This study focuses on reducing cesarean births among first-time mothers with term, singleton, vertex pregnancies, especially Black birthing people. It also aims to enhance patient experience and promote respectful care through patient participation in decision-making on labor units. The study compares the TeamBirth intervention, which uses a train-the-trainer model to support shared decision-making huddles, against usual care practices. Participants will be randomly assigned to either the TeamBirth program or usual care. The evaluation measures outcomes before and after TeamBirth implementation over specific timeframes. Participants will be monitored for cesarean birth rates and shared decision-making levels six months before and three months after the intervention starts. Patient experience is also assessed during these periods. The study includes English or Spanish speaking individuals aged 18 or older who gave birth after laboring. Outcomes focus on both overall and Black birthing people, with follow-up planned until July 2029.
Actively Recruiting
Researchers are conducting the FLEX Registry, a large-scale, population-based study focusing on patients with stage I to III breast cancer who have undergone MammaPrint and BluePrint testing on their primary breast tumors. This observational registry aims to gather comprehensive full genome expression data linked with clinical information to explore new gene associations that may have prognostic or predictive value. The design is adaptive, allowing additional targeted substudies and arms to be added over time for more specific investigations. All participants will have their tumor samples tested using MammaPrint and BluePrint through the full-genome testing array provided by Agendia. Treatment decisions are made by the treating physician following NCCN guidelines or recognized alternatives, with no specific treatment mandated by the study. The registry plans to enroll about 30,000 patients from more than 125 US institutions, encompassing various treatment arms detailed in study appendices. Participants will have clinical data collected online at multiple time points at enrollment, during treatment, and at 1, 3, 5, and 10 years after diagnosis. This long-term follow-up allows researchers to study gene expression alongside clinical outcomes, supporting the creation of subgroup analyses and future targeted trials. The primary outcomes include establishing a large-scale full genome expression registry and providing infrastructure for examining smaller patient groups over the 10-year study period.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate the use and safety of Motiva Implants in people undergoing breast implant procedures. The study focuses on collecting and assessing safety and effectiveness data about these implants after they have been approved and are in general use. It includes participants who have primary breast augmentation, revision breast augmentation, or other aesthetic surgeries, with a focus on female patients aged 22 and older. Participants will receive Motiva Implants as part of their breast surgery or undergo other aesthetic procedures. The study is prospective and non-randomized, with data collected at baseline before surgery, during the operation, and annually for up to 10 years after surgery. Participants who have revision surgery or other aesthetic procedures without implants are also included as control groups to compare outcomes. During the study, participants will have various assessments including medical imaging such as CT, ultrasound, or MRI if medically advised. Researchers will monitor for connective tissue disease signs and symptoms, reproductive complications, cancer diagnoses, local complications, and patient satisfaction over 10 years. The impact of RFID on imaging will also be assessed. Participants will be followed for up to 10 years, providing long-term data on the safety and performance of Motiva Implants.
Actively Recruiting
Migraine is a common neurological disorder causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. This research aims to evaluate the safety and effectiveness of ubrogepant, a medication approved for adults, in treating acute migraine attacks in children and adolescents aged 6 to 17 years. The study includes two groups a pharmacokinetic PK cohort for younger children and a main randomized study involving both children and adolescents. Participants aged 6 to 11 in the PK cohort will receive two different doses of ubrogepant to determine the appropriate dose for the main study. In the main study, after dose selection, children aged 6 to 11 and adolescents aged 12 to 17 will be randomly assigned to receive either a low dose, high dose of ubrogepant, or placebo, with a 1 in 3 chance of placebo assignment. For qualifying migraine attacks, participants will take oral tablets of the assigned study intervention and may take a second dose or rescue medication at least 2 hours later if the headache persists. Participants will attend regular visits at a hospital or clinic for up to 6 months. Researchers will monitor the effects of treatment through medical assessments, blood tests, side effect checks, and questionnaires. The main outcome measured is the percentage of participants who are free from pain 2 hours after the initial dose. Safety and tolerability will also be assessed throughout the study duration.